Search research articles
Contact Us
Filters
Showing results (51-60 of 68) with videos related to
Page
of 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2024
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
David J Pinato, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
JAMA Oncology
|
August 24, 2023
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Enrui Xie, Yee Hui Yeo, Bernhard Scheiner, et al.
JHEP Reports : Innovation in Hepatology
|
July 18, 2025
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
Einstein (Sao Paulo, Brazil)
|
January 14, 2016
Iron overload in Brazilian thalassemic patients
Reijane Alves de Assis, Fernando Uliana Kay, Laércio Alberto Rosemberg, et al.
Hepatology International
|
April 3, 2023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Hepatology (Baltimore, Md.)
|
March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study
Antonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.
Cancers
|
December 11, 2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Yue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, et al.
Cancers
|
January 11, 2022
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
Ambreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, et al.
Journal of Hepatocellular Carcinoma
|
April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 68) with videos related to
Sort By:
Page
of 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2024
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
David J Pinato, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
JAMA Oncology
|
August 24, 2023
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Enrui Xie, Yee Hui Yeo, Bernhard Scheiner, et al.
JHEP Reports : Innovation in Hepatology
|
July 18, 2025
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
Einstein (Sao Paulo, Brazil)
|
January 14, 2016
Iron overload in Brazilian thalassemic patients
Reijane Alves de Assis, Fernando Uliana Kay, Laércio Alberto Rosemberg, et al.
Hepatology International
|
April 3, 2023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Hepatology (Baltimore, Md.)
|
March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study
Antonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.
Cancers
|
December 11, 2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Yue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 23, 2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, et al.
Cancers
|
January 11, 2022
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
Ambreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, et al.
Journal of Hepatocellular Carcinoma
|
April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
Bernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
Page
of 7